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Abstract
ABCG2 is one of at least three human ATP binding cassette (ABC) transporters which can facilitate the export
from cells of a wide range of chemically unrelated drug molecules. This capacity for multidrug transport
is not only a confounding factor in chemotherapy, but is also one of the more perplexing phenomena in
transporter biochemistry. Since its discovery in the last decade of the 20th century much has been revealed
about ABCG2’s localization, physiological function and its broad substrate range. There have also been many
investigations of its structure and molecular mechanism. In this mini review article we take a Rumsfeldian
approach to ABCG2 and essentially ask what we do know about this transporter, and what we will need to
know about this transporter if we wish to use modulation of ABCG2 activity as a therapeutic approach.
Multidrug transporters in biology
Multidrug resistance (MDR) can be defined as the ability
of cells or organisms to resist the cytotoxic effects of a
diverse range of chemical structures, often with different
intracellular targets. MDR is observed across the spectrum
of infectious disease therapy, as well as being documented
in cancer chemotherapy. In many cases, the acquisition
of a MDR phenotype is a poor prognostic indicator. For
example, the emergence of drug resistant pathogenic bacteria
and the subsequent lack of effective therapies is one of the
global challenges for the 21st century. MDR may manifest
through many mechanisms, often operating with what one
presumes to be a degree of synergy, including chemical
modification of the drug molecule rendering it ineffective (or
less effective) and the alteration of gene expression to enable
cellular metabolism to proceed through other pathways. The
mechanism of interest here is the export of the drug from
the cell, thus preventing it from achieving clinically effective
concentrations. MDR by drug export is catalysed by at
least 5 (and almost certainly more) families of membrane
proteins with examples well documented in antimicrobial,
antiparasitic and anticancer chemotherapy [1].
In humans,MDR ismostwidely associatedwith the failure
of cancer chemotherapy. A number of cancers have been
shown to have poorer prognosis if there is either a pre-
existing expression of an MDR pump, or if expression of an
MDRpump develops as a result of chemotherapy (see section
below). Several human ATP binding cassette (ABC) proteins
have been well described to be capable of MDR, although
doubtless there will be more from the 48 ABC proteins
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that comprise the family in humans. Three of these, ABCB1
(P-glycoprotein), ABCC1 (multidrug resistance protein 1)
and ABCG2 (breast cancer resistance protein) have been the
subject ofmanydecades of investigation, and there are already
numerous reviews onmany facets of their structure, function,
regulation and role in disease [2,3]. The aim here is not to
provide an exhaustive overview of one of this triumvirate
(ABCG2)but to present a personal viewaboutwhatweknow,
and what we need to know about this transporter if we are to
develop rational interventions in chemotherapy.
ABCG2 localization and physiological
function: an incomplete picture
Although first isolated from multidrug resistant cancer cells,
ABCG2’s expression and distribution pattern in normal
tissues implies that it must fulfil important physiological
roles, such as protecting the organism as a first line of defence
against environmental toxins. Schinkel’s original study
on ABCG2-null mice confirmed this role, demonstrating
that these animals are more susceptible to diet-induced
protoporphyria and phototoxicity, caused by accumulation
of pheophorbide A [4], a chlorophyll degradation product
and a confirmed ABCG2 transport substrate [5].
Extensive studies have continued to affirm that in humans
and rodents, the localization of ABCG2 can play a vital
role in limiting absorption (in the small intestine), mediating
distribution (e.g. in the blood–brain and blood–placental
barriers) and facilitating elimination and excretion (in the
liver and kidney) of drugs or xenobiotics that are ABCG2
transport substrates. This specific ABCG2 distribution
profile among the different types of tissues is closely related
to the physiological role it assumes in the body. For instance,
in the blood–brain barrier, ABCG2 is expressed highest on
the luminal side of brain endothelial cells. Here, it serves
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as a crucial barrier to drug access, significantly limiting the
penetration of drugs or xenobiotics into the brain [6,7],
potentially in a synergistic manner with ABCB1 [8], with
implications for brain tumour therapy and imaging [9].
In addition,ABCG2 is expressed in the apicalmembrane of
epithelial cells in the gastrointestinal (GI) tract, with highest
expression in the duodenum and a gradual decrease along the
GI tract to the rectum.Here, ABCG2 plays an important role
in limiting the absorption of orally administered anticancer
drugs and ingested toxins [10,11]. In the liver canalicular
membranes, where ABCG2 is constitutively expressed, a
role in toxin and metabolite excretion is apparent [11,12].
In the human kidney ABCG2 is expressed on the apical
membrane of proximal tubular cells, however with a lower
expression level than that in the liver and the small
intestine, and is responsible for urate export. Indeed, ABCG2
activity as a urate transporter is known to be abrogated in
gout [13].
Among normal human tissues, ABCG2 is expressed
highest on the apical membrane of the placental syncytio-
trophoblasts.Here,ABCG2 expels drugs or xenobiotics from
the foetal compartment back to the maternal circulation,
limiting foetal exposure of the toxic substances and playing a
major role in protecting foetus against maternally derived
toxins [14]. ABCG2 is also expressed in the mammary
gland being induced strongly during the lactation phase
in mice, cows, and humans. It has been shown that
ABCG2 actively transports not only beneficial vitamins (e.g.
riboflavin) but also, seemingly paradoxically, toxic drugs
and xenobiotics (e.g. topotecan, cimetidine and 2-amino-1-
methyl-6-phenylimidazo [4,5-b] pyridine) into breast-milk
[15,16].
How do we develop a greater understanding of the tissue-
specific roles of ABCG2? This question remains important
to answer, particularly considering the impact of ABCG2
function onmultiple drug pharmacokinetics and the potential
for ABCG2 polymorphisms to have differential effects on
transporter function (see below).
ABCG2 transport substrate diversity and
pharmacology: all mapped out?
As discussed above, the exact physiological roles of ABCG2
remain somewhat enigmatic. The distribution of the trans-
porter within tissues that have a predominantly secretory
or barrier function leads to ABCG2 being recognised for
a role in controlling the disposition and tissue exposure
of endobiotics and xenobiotics, confirmed in numerous
in vitro and in vivo studies. These include antibiotics,
sterols, immune-suppressants (including anti-HIV drugs),
fluorescent dyes (e.g. Hoechst 33342), photosensitizers
(pheophorbide A and protoporphyrin IX). The increased
expression of ABCG2 has been linked to MDR in cancer
(see below) and there have also been numerous studies
describing ABCG2 mediated transport of chemotherapeutic
drugs including mitoxantrone, methotrexate, topotecans,
flavopiridol and tyrosine kinase inhibitors (imatinib, gefitinib
and nilotinib) [17].
At present, over 200 transport substrates of ABCG2
have been identified, with some attempts made to analyse
structure–activity relationships (SAR). One such study
demonstrated the impact of polarity on transport in a series of
novel camptothecin analogues, which were actively extruded
at a greater rate dependent on their higher polarity [18].
Additionally, small chemical libraries of ABCG2 inhibitors
have been investigated to determine important functional
groups. For example, inhibitors of casein kinase II were
repurposed into a series of ABCG2 inhibitors by an
overall increase in hydrophobicity and aromaticity [19]. This
argument for polarity being associated with transport, and
hydrophobicity with inhibition is interesting when taken
alongside themost thorough attempt to determine the typical
features ofABCG2 interacting compounds, presented in 2015
by Anna Seelig’s group [20,21]. In two papers they employed
functional ATPase activity assays, physicochemical data and
molecular modelling to attempt to distinguish between the
chemistries of ABCB1 and ABCG2 transport substrates.
The authors argued that ABCG2 transports chemistries with
higher hydrophilicity than ABCB1. However, in common
with ABCB1, it does so subsequent to the partitioning of
compounds from the aqueous to the lipid phase. A loose set
of rules incorporating hydrophobicity, amphipathicity and
ionization state was derived from analysis of a test series
of chemicals to predict ABCG2’s likely interaction with or
inhibition by other compounds [21]. Given the hundreds
of compounds within the repertoire of ABCG2’s chemical
interactome it would be interesting to see how these rules
evolve with the acquisition of further data.
What do we know about how andwhere these drugs bind?
The short answer: surprisingly little! Initial studies aimed to
understandABCG2pharmacology, and included equilibrium
andkinetic radioligandbinding assays to study the interaction
of radiolabelleddaunomycinwithABCG2expressed in insect
(Sf9) cell membranes [22]. This study was performed with an
R482Gmutant versionofABCG2due to its broader substrate
range (see below). The data demonstrated an affinity (Kd) of
ABCG2 for daunomycin of approximately 100 nM, which
is still the only quantitative demonstration of an affinity
of ABCG2 for a transport substrate. Relative potencies for
other drugs (mitoxantrone, Hoechst 33342, doxorubicin and
prazosin) to displace daunomycin binding were obtained
and led to a picture of multiple drug binding sites showing
a complex network of allosteric communications [22].
Changes in transport substrate affinity were demonstrated
in subsequent studies upon the binding, rather than the
hydrolysis of ATP [23], but other direct, quantitative
data for ABCG2:transport substrate interaction remain
scarce.
In the absence of such data a great deal of time and
effort has been put into in vitro site-directed mutagenesis
studies of ABCG2. Arginine 482 to glycine/threonine (TM3;
Figure 1) is a classic example of a mutation which impacts
substrate binding and/or transport resulting in the ability
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence
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Figure 1 Topology and functionally important residues of ABCG2
A monomer of ABCG2 consists of a 655 amino acid protein with a 250 amino acid intracellular N-terminal NBD, an
uncharacterized linker region followed by six TMDs and associated intra and extracellular loops. Orange colours indicate
where the experimental and predicted topology differ. A number of residues have been identiﬁed as signiﬁcant including
glycosylation site (green), stability affecting sites (red) and putative drug binding sites (yellow) in addition to the gout
associated Q141K polymorphism are shown.
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to transport daunorubicin, rhodamine 123 and lyso-tracker
green. The mutant protein is also able to transport most wild
type ABCG2 substrates, with the exception of methotrexate
[24,25]. Mutations at residues T402(A/R), P485(A), P392(A),
M549(A) also appear to be implicated in binding and
transport of mitoxantrone, Hoechst 33342 and BODIPY-
prazosin [5,26,27].
ABCG2 has over 80 single nucleotide polymorphisms
(SNPs) residing within its gene coding region. The effect
of ABCG2 polymorphisms on clinical pharmacology is a
crucial area of current research; given the polyspecificity
of the transporter it is inevitable that some polymorphisms
will impact on the pharmacokinetics of particular drugs.
Perhaps the most well documented of these is the rs2231142
polymorphism, Q141K. This polymorphism (which is
associated with increase prevalence of gout [13]) has also
been found to increase the bioavailability of topotecan, also
more than doubling the exposure to rosuvastatin, commonly
used in the treatment of hypercholesterolaemia [28,29].
That a single polymorphism can lead to raised levels of
drugs or metabolites by either inhibiting excretion (i.e. renal
elimination of urate [13]) or inhibiting absorption (intestinal
uptake of rosuvastatin [29]) is intriguing and presents a
challenge in understanding drug pharmacokinetics. Clearly,
the impact of other SNPs on ABCG2 expression, drug
transport and selectivity will be an increasingly important
area of research.
ABCG2 structure and oligomerization:
building up the picture is taking time
Protein structure is vital for a full understanding of function
and could provide an excellent basis for the design of
drugs. For the ABC multidrug pumps which are targets for
pharmacological intervention thiswill require high resolution
crystal structures in several conformations, including with
bound transport substrate. In the absence of this for ABCG2,
we have had to rely on the evidence for the transporter’s
membrane topology, its oligomeric state and available low
resolution structural data, as the framework upon which to
pin our understanding of mechanism.
Eukaryotic ABC transporters consist of at least one
cytoplasmic nucleotide binding domain (NBD) and one
transmembrane domain (TMD; Figure 1). The fundamental
functional unit of ABC transporters requires the interaction
of 2 NBDs to provide composite ATP binding sites,
with contributions from both NBDs [30]. Eukaryotic
ABC transporters meet this requirement either as ‘full
transporters’, typically consisting of two homologous halves
comprising a TMD-NBD-TMD-NBD arrangement, or
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as ‘half-transporters’ (comprising a single TMD-NBD)
that form homo-dimers, hetero-dimers or higher order
oligomers. The ABCG subfamily falls into the half-
transporter category and have their TMD-NBD arrangement
reversed. Subsequently, human ABCG2 is a reverse half
transporter [31]. Six transmembrane helices are identified
by consensus topology prediction algorithms and confirmed
by epitope tagging, although there are differences in the
predicted, compared with experimental, topology in terms
of the location of TM2 and TM5 [32], which may be both
shifted C-terminally with respect to the computer-based
predictions (Figure 1). Whether this reflects the insertion
of tags having an effect on the structure is unclear in the
absence of further supporting evidence [2]. Without a high
resolution structure, homology modelling has been used to
assist in the interpretation of experimental data, although
this has been rightly indicated as a hazardous venture due
to the low sequence identity (often less than 20% [20])
and the 120 amino acid NBD-TMD linker region which is
unique to the ABCG family of transporters and so cannot
be modelled reliably from other ABC transporter structures
(Figure 1). Models based upon the bacterial NBD MalK
(i.e. to model the ABCG2 NBD), bacterial half-transporters
Sav1866 and MsbA and the full length mouse ABCB1
have been described and their use to date has been limited
to interpreting low resolution electron microscopy (EM)
data [33,34]. Improved structural data of ABCG2 in the
inward facing, presumably nucleotide-free state have been
obtained recently [35], but this is far short of secondary
structural resolution; perhaps the incredible advances that
have made in data collection and analysis in cryo-EM in
recent years (see [36] for a review) will enable us to reach
near atomic resolution for ABCG2 in the not too distant
future.
Based on knowledge of other ABC transporters it was
probable that ABCG2 would require at least dimerization to
form a functional unit. However, evidence for higher order
oligomers has come thick and fast. The demonstration of tet-
ramer formation has included native gel electrophoresis and
EM [37,38] and other EM studies identified a stable homo-
octameric association [33].More recently, the oligomeric state
has been studied in intact membranes in live and fixed cells;
both fluorescence correlation spectroscopy and stepwise
photobleaching enabled the observation of a predominantly
tetrameric organization of ABCG2 in the presence and
absence of transport substrates [39]. Understanding the
structural basis of oligomerization remains problematic; the
entire TM5–TM6 region appears to be involved with some
evidence that this helical pair is sufficient for oligomerization
to occur [40]. Within this region the single glycosylation
site (N596; [41]) and an intramolecular disulfide bond
between C592 and C608 [42] are implicated in protein
trafficking and stability. A further cysteine residue in the
TM5–TM6 extracellular loop (C603) is involved in inter-
molecular disulfide bond formation although mutation of
this residue does not impede oligomerization nor transport
activity [43,44].
When will this structural knowledge enable us to inhibit
any unwanted actions of ABCG2? Tellingly, more than a
decade on from the initial discovery of ABCG2-specific
inhibitors, the mechanism of fumitremorgin C and Ko143
remains obscure [45]. It remains to be seen whether a better
understanding of the structural basis for drug interaction,
or a better understanding of oligomerization is required to
provide a route towards therapeutic inhibition of ABCG2.
ABCG2 in cancer: did we cry wolf?
ABCG2 was originally cloned from breast tumour cell
lines and placental tissue in 1998 [46–48] and its isolation
from a multidrug resistant breast cancer (Mcf7-derived) cell
line quickly led to its assignation as the ‘breast cancer
resistance protein’. But how justifiable has that moniker
proven to be? Indeed, how much of a prognostic indicator is
ABCG2 expression in cancer?A trawl of the literature reveals
relatively few cancer types where ABCG2 expression (either
protein or mRNA) is an independent prognostic indicator
of poor clinical outcome. For haematological malignancies
there is considerable evidence that ABCG2 is associated
with poor outcome in acute myeloid leukaemia [49,50],
even after bone marrow transplantation [51], and diffuse
large B-cell lymphoma [52]. In some of these studies, co-
expression with other MDR pumps (notably ABCB1) was
associated with even higher hazard ratios [53,54]. For acute
lymphoblastic leukaemia (ALL) the evidence is rather less
convincing [55], and in paediatric ALL multiple studies
report no associationbetweenABCG2expression and clinical
outcome [56,57]. In solid tumours the picture is very mixed.
For many tumour types there are frequently only 1 or
2 studies available precluding any conclusions from being
drawn. Even for breast cancer the number of studies remains
low with conflicting data presented [58,59]. For lung and
oesophageal cancer, which have dismal 5-year survival rates
(less than 20%), there is a consensus developing that ABCG2
is a prognostic indicator. In both small cell and non-small
cell lung cancer (NSCLC) multiple studies now identify
ABCG2 expression as being correlated with lower overall
survival, shorter progression-free survival and the response
to therapy [52,60–64]. Intriguingly, this applies when the
therapy is platinum based, although ABCG2 is not identified
as a transporter of Pt-containing drugs.
The identification of ABCG2 as a cancer stem cell marker
[65] has led tomany papers attempting to identify cancer stem
cells co-expressing the marker CD133 andABCG2, although
in only a limited number of cases is co-expression of CD133
and ABCG2 of prognostic significance [61]. Attention
is also turning in clinical studies to whether particular
SNPs of ABCG2 are predictive of response to treatment,
or chemotherapy induced toxicity. Again, haematological
malignancies lead the way in these studies although recent
data onNSCLC and ovarian cancer indicate that a more fine-
grained analysis ofABCG2haplotypeswill uncover clinically
relevant findings [66].
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Perspective
So what now for ABCG2 research? In our own field
(structure and function) we would hope that the bounty
of functional data soon has more robust structural models
within which these data can be interpreted. That will help
us to develop a more complete understanding of how drugs
are bound and transported by this MDR pump. It will also
help us to interpret the action of small molecule inhibitors
of ABCG2, which may emerge to be important in clinical
practice. In this regard, we need more studies to examine
ABCG2 expression in solid tumours to consolidate the data
already in the literature and provide a more definitive picture
of this pump’s role in cancer biology.
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